NCT04857645 - ASTX727 and Donor Lymphocyte Infusions After Allogenic Stem Cell Transplantation in Very High Risk MDS or AML Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 22, 2021

Primary Completion Date

April 30, 2024

Study Completion Date

April 22, 2025

Conditions

MDSAML

Interventions

DRUG

ASTX727

Eligible patient started ASTX727 between 40 and 130 days after allogenic stem cell transplantation

OTHER

Donor Lymphocyte Infusions

In absence of previous grade 2-4 or chronic graft-versus-host disease (GVHD), DLI will be administered at increasing doses the first day of ASTX727 cycles

Trial Locations (12)

31059

IUCT Oncopole - Département d'hématologie - Service de greffe de cellules souches hématopoïétiques, Toulouse

33604

CHU de Haut-Lévèque de Bordeaux - Service des maladies du sang, Pessac

34295

Hôpital Saint Eloi - Service hématologie clinique, Montpellier

38043

CHU de Grenoble - Clinique Universitaire d'hématologie, Grenoble

44093

CHU Hôtel Dieu - Service hématologie clinique, Nantes

49933

CHU d'Angers - Service des maladies du sang, Angers

54511

CHU Brabois - Service hématologie clinique, Vandœuvre-lès-Nancy

63000

CHU Estaing - Service hématologie clinique et thérapie cellulaire, Clermont-Ferrand

69645

CH Lyon Sud - Servide Hématologie, Pierre-Bénite

75010

Hôpital Saint Louis - Service hématologie-greffe, Paris

76038

Centre Henri Becquerel - Département d'hématologie, Rouen

80054

CHU d'Amiens Picardie - Site sud - Service hématologie clinique et thérapie cellulaire, Amiens